Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
As increasingly complex, poorly water-soluble molecules enter development, AustinPx helps developers look beyond near-term ...
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol ...
Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more ...
The finalists for the 2026 CPHI Pharma Awards span15 categories including API development, digital transformation, ...
On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...
The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...
David S. Thompson, CSAP, is Chief Alliance Officer at Eli Lilly and Company.
Marco Anelli, MD | Authors | Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.
In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results